drug · small molecule

NUCYNTA ER

updated 3mo ago

by $COLL COLLEGIUM PHARMACEUTICAL, INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 6

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for 4 indications.

targets

Sodium-dependent noradrenaline transporterMu-type opioid receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

NUCYNTA ER

trade names

Nucynta, Nucynta er, Palexia

generic

TAPENTADOL HYDROCHLORIDE

MOA

12.1 Mechanism of Action Tapentadol is a centrally-acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu-opioid receptor (MOR) agonist and a norepinephrine reuptake inhibitor (NRI). Analgesia in animal models is derived from both of these properties.

indication

1 INDICATIONS AND USAGE NUCYNTA ER (tapentadol) is indicated for the management of: Severe and persistent pain in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. NUCYNTA ER is an opioid agonist indicated for the management of: severe and persistent pain in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including NUCYNTA ER, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) NUCYNTA ER is not indicated as an as-needed (prn) analgesic. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including NUCYNTA ER, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. NUCYNTA ER is not indicated as an as-needed (prn) analgesic.

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 2m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

NUCYNTA ER

updated 3mo ago

by $COLL COLLEGIUM PHARMACEUTICAL, INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 6

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for 4 indications.

targets

Sodium-dependent noradrenaline transporterMu-type opioid receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

NUCYNTA ER

trade names

Nucynta, Nucynta er, Palexia

generic

TAPENTADOL HYDROCHLORIDE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 2m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

NUCYNTA ER

🐶 often sniffed alongside

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

NUCYNTA ER

🐶 often sniffed alongside

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)